

# The Oncology Institute Announces Third Quarter 2022 Earnings Release Date and Conference Call

## October 19, 2022 12:01 PM EDT

CERRITOS, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter results after the market close on Wednesday November 9, 2022, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13732555. The replay will be available until November 16, 2022.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at <a href="https://investors.theoncologyinstitute.com/">https://investors.theoncologyinstitute.com/</a>.

### **About The Oncology Institute**

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit <a href="https://www.theoncologyinstitute.com">www.theoncologyinstitute.com</a>.

#### Contacts

#### Media

The Oncology Institute
Julie Korinke
juliekorinke@theoncologyinstitute.com
(562) 735-3226 x 88806

Juan Lezama juanlezama@theoncologyinstitute.com (562) 374-8434

### Investors

Solebury Strategic Communications Maria Lycouris investors@theoncologyinstitute.com